{
    "organizations": [],
    "uuid": "38ba83ea3a5952236ecdddfd815a1590426a8c20",
    "author": "",
    "url": "https://www.reuters.com/article/brief-seattle-genetics-announces-fda-app/brief-seattle-genetics-announces-fda-approval-of-adcetris-idUSASC09T0X",
    "ord_in_thread": 0,
    "title": "BRIEF-Seattle Genetics Announces FDA Approval Of Adcetris",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 20, 2018 / 5:14 PM / Updated 22 minutes ago BRIEF-Seattle Genetics Announces FDA Approval Of Adcetris Reuters Staff 1 Min Read March 20 (Reuters) - Seattle Genetics Inc: * SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA * SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE MAY 1, 2018​ * SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-20T19:13:00.000+02:00",
    "crawled": "2018-03-20T19:52:18.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "genetics",
        "announces",
        "fda",
        "approval",
        "adcetris",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "seattle",
        "genetics",
        "inc",
        "seattle",
        "genetics",
        "announces",
        "fda",
        "approval",
        "brentuximab",
        "vedotin",
        "combination",
        "chemotherapy",
        "adult",
        "previously",
        "untreated",
        "stage",
        "iii",
        "iv",
        "classical",
        "hodgkin",
        "lymphoma",
        "seattle",
        "genetics",
        "inc",
        "drug",
        "user",
        "fee",
        "act",
        "target",
        "action",
        "date",
        "may",
        "seattle",
        "genetics",
        "inc",
        "also",
        "granted",
        "priority",
        "review",
        "supplemental",
        "biologics",
        "license",
        "application",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}